RGNX
HEALTHCARERegenxbio Inc
AI Insight
What's Moving RGNX Today?
No stock-specific AI insight has been generated for RGNX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.46$16.19
$9.95
Fundamentals
Market Cap$459M
P/E Ratio—
EPS$-5.60
Dividend Yield—
Dividend / Share—
ROE-196.4%
Profit Margin—
Debt / Equity—
Trading
Volume3.0M
Avg Volume (10D)—
Shares Outstanding51.7M
RGNX News
38 articles- REGENXBIO Inc. Stock 12‑Month Price Target Raised to $26.08, Implies 234% UpsideTradingView·Jun 23, 2026
- Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS IIYahoo Finance·Jun 23, 2026
- FDA changes rare disease tune again as it clears path for Regenxbio’s gene therapyPharmaceutical-technology·Jun 23, 2026
- Sector Update: Healthcare Stocks Rise Late AfternoonYahoo Finance·Jun 22, 2026
- AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock MoversYahoo Finance·Jun 22, 2026
- RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbio’s Hunter Syndrome TherapyStocktwits·Jun 22, 2026
- Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejectionBiopharmadive·Jun 22, 2026
- REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS IIYahoo Finance·Jun 22, 2026
- Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC SaysYahoo Finance·Jun 18, 2026
- Are Options Traders Betting on a Big Move in REGENXBIO Stock?Yahoo Finance·Jun 16, 2026
- JPMorgan affiliates report 4.4% stake in REGENXBIO (RGNX) in 13G/AStock Titan·Jun 4, 2026
- Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage CareYahoo Finance·Jun 3, 2026
- How The REGENXBIO (RGNX) Investment Story Is Evolving Without New Analyst CommentaryYahoo Finance·Jun 2, 2026
- Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash RunwayYahoo Finance·May 20, 2026
- REGENXBIO to Participate in Upcoming Investor ConferencesYahoo Finance·May 18, 2026
- Regenxbio (RGNX) Q1 2026 Earnings TranscriptMotley Fool·May 18, 2026
- Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to ...Yahoo Finance·May 14, 2026
- Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary EndpointYahoo Finance·May 14, 2026
- Regenxbio Shares Rise After Positive Duchenne Trial ResultsAdvfn·May 14, 2026
- Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 14, 2026
- REGENXBIO Reports First Quarter 2026 Financial Results and Operational HighlightsYahoo Finance·May 14, 2026
- REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202Yahoo Finance·May 14, 2026
- REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNXBenzinga·Apr 15, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNXGlobeNewswire Inc.·Apr 14, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APEGlobeNewswire Inc.·Apr 14, 2026
- REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNXGlobeNewswire Inc.·Apr 12, 2026
- Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 6, 2026
- RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmBenzinga·Apr 6, 2026
- ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNXGlobeNewswire Inc.·Apr 5, 2026
- TCPC IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages BlackRock TCP Capital Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – TCPCGlobeNewswire Inc.·Apr 5, 2026
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNXGlobeNewswire Inc.·Apr 5, 2026
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the FirmGlobeNewswire Inc.·Apr 3, 2026
- ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Snowflake Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SNOWGlobeNewswire Inc.·Apr 1, 2026
- RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc.·Mar 30, 2026
- REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNXBenzinga·Mar 30, 2026
- RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmBenzinga·Mar 30, 2026
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Franklin BSP Realty Trust, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FBRTGlobeNewswire Inc.·Mar 26, 2026
- ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNXGlobeNewswire Inc.·Mar 26, 2026
All 38 articles loaded
Price Data
Open$8.94
Previous Close$9.07
Day High$10.34
Day Low$8.94
52 Week High$16.19
52 Week Low$5.46
52-Week Range
$5.46$16.19
$9.95
Fundamentals
Market Cap$459M
P/E Ratio—
EPS$-5.60
Dividend Yield—
Dividend / Share—
ROE-196.4%
Profit Margin—
Debt / Equity—
Trading
Volume3.0M
Avg Volume (10D)—
Shares Outstanding51.7M
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—